Eribulin for heavily pre-treated metastatic breast cancer patients

Table 3 Clinical response rates of evaluable patients with metastatic breast cancer treated with eribulin n (%)

	All evaluable patients in the series (n = 18)	95%CI	3 or less previous lines of therapy (n = 8)	95%CI	More than 3 previous lines of therapy (n = 10)	95%CI
CR	0	0	0	0	0	0
PR	7 (38.9)	16.4-61.4	4 (50)	18.7-81.8	3 (30)	1.6-58.4
SD	3 (16.7)	0-33.9	2 (25)	0-55	1 (10)	0-28.6
PD	8 (44.4)	21.5-67.4	2 (25)	0-55	6 (60)	33.2-86.8

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.